FGF23 and hydrops fetalis: Of these, 2 proteins (ADM and Gal-3) are currently under evaluation in clinical trials for HF, and 5 (CHI3L1, CSF-1, CTSL1, FGF-23, and MMP-12) represent novel putative therapeutic targets for HF.